(September 18, 2024, Kunming)- Walvax Biotechnology Co., Ltd. ("Walvax", together with its subsidiaries, the "Group", stock code: 300142.SZ) is pleased to announce that MSCI has upgraded its Environmental, Social, and Governance (ESG) rating to BBB in September 2024 assessment. This upgrade reflects Walvax's ongoing commitment to sustainable and responsible business practices in the biotechnology sector.

Key Highlights from the MSCI ESG Report:

1. Access to Healthcare: Walvax demonstrated robust initiatives to capitalize on access to healthcare opportunities, scoring above the industry average. The company has a significant presence in emerging markets with sizeable underserved populations.
2. Product Safety & Quality: Walvax's performance in this area exceeded industry standards. Research suggests fewer regulatory warnings compared to peers, underscoring the company's dedication to maintaining high standards in product development and manufacturing.
3. Environmental Impact Management: The company has implemented robust initiatives to address environmental impacts from air, water, and waste emissions relative to peers, showcasing its commitment to minimizing its ecological footprint.
4. Corporate Behavior: Walvax has established detailed policies on business ethics and anti-corruption measures, reflecting its commitment to operating with integrity and transparency.

"We are proud to receive this ESG rating upgrade from MSCI," said Mr. Wei Yao, CEO of Walvax Biotechnology. "This recognition underscores our ongoing efforts to integrate sustainability into our core business practices while advancing biotechnology innovations that improve global health outcomes." 

The upgrade to BBB highlights Walvax's progress in managing ESG risks and opportunities, particularly in areas critical to the biotechnology industry such as access to healthcare, product safety, and environmental stewardship. The company has made significant contributions to social welfare, including donations exceeding RMB25 million and the donation of over 1 million doses of bivalent HPV vaccines and 23-valent pneumococcal polysaccharide vaccines to various charitable organizations. Walvax also continues to promote health initiatives such as the "Love Baby Action" and "Rose Action" campaigns.

Walvax remains committed to further enhancing its ESG performance and will continue to invest in sustainable practices that benefit its stakeholders, including children and women, people in need, employees, shareholders, and the communities it serves.

About Walvax

Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines. Headquartered in China's southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines. With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, Walvax's purpose is to help everyone live a healthy life and has delivered vaccine products to 21 countries. For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.

About MSCI ESG Research

MSCI ESG Research provides in-depth research, ratings, and analysis of the environmental, social, and governance-related business practices of thousands of companies worldwide. Their comprehensive research process is designed to identify and analyze ESG risks and opportunities that can impact the long-term sustainability of companies.